Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporin A

Chim C. Lang, Iain S. Henderson, Robert Mactier, William K. Stewart, Allan D. Struthers

    Research output: Contribution to journalArticlepeer-review

    15 Citations (Scopus)

    Abstract

    Objective: Atrial natriuretic factor (ANF) has several properties which suggest that it may ameliorate cyclosporinA nephrotoxicity. We therefore investigated the response to a pharmacological dose of ANF in renal transplant recipients treated with cyclosporinA
    Design: A single-blind randomized crossover design comparing the renal and haemodynamic effects of D-glucose (placebo) with ANF.
    Methods: Seven patients with stable renal function following renal transplantation were studied under maximal water diuresis. Glomerular filtration rate and effective renal plasma flow were estimated from clearances of inulin and para-aminohippurate, respectively
    Results: Plasma ANF levels increased significantly in association with increased diuresis and natriuresis. Glomerular filtration rate was unchanged after placebo but increased significantly after ANF fusion. Likewise, effective renal plasma flow increased significantly with ANF infusion. There was a significant fall in systolic blood pressure, with no apparent change in heart rate and diastolic blood pressure
    Conclusions: These results suggest that ANF may have beneficial effects in protecting against cyclosporin A-induced nephrotoxicity and hypertension

    (C) Lippincott-Raven Publishers.
    Original languageEnglish
    Pages (from-to)483-488
    Number of pages6
    JournalJournal of Hypertension
    Volume10
    Issue number5
    Publication statusPublished - May 1992

    Keywords

    • Atrial natriuretic peptide
    • Cyclosporin A
    • Nephrotoxicity
    • Hypertension
    • Renal function

    Fingerprint

    Dive into the research topics of 'Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporin A'. Together they form a unique fingerprint.

    Cite this